CMRX - Chimerix, Inc.

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
4.32
-0.07 (-1.59%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close4.39
Open4.38
Bid3.50 x 500
Ask10.00 x 100
Day's Range4.32 - 4.44
52 Week Range4.17 - 6.64
Volume1,242,988
Avg. Volume252,644
Market Cap203.592M
Beta2.06
PE Ratio (TTM)N/A
EPS (TTM)-1.43
Earnings DateFeb 28, 2018 - Mar 5, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.60
Trade prices are not sourced from all markets
  • Thomson Reuters StreetEventslast month

    Edited Transcript of CMRX earnings conference call or presentation 8-Nov-17 1:30pm GMT

    Q3 2017 Chimerix Inc Earnings Call

  • Should You Buy Chimerix Inc (CMRX)?
    Simply Wall St.last month

    Should You Buy Chimerix Inc (CMRX)?

    Chimerix Inc (NASDAQ:CMRX), a biotechnology company based in United States, saw a decent share price growth in the teens level on the NasdaqGM over the last few months. As aRead More...

  • Associated Presslast month

    Chimerix reports 3Q loss

    On a per-share basis, the Durham, North Carolina-based company said it had a loss of 37 cents. The results surpassed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...

  • GlobeNewswirelast month

    Chimerix Announces Third Quarter 2017 Financial Results

    DURHAM, N.C., Nov. 08, 2017-- Chimerix, a biopharmaceutical company developing novel antivirals to address unmet medical needs, today reported financial results and provided a corporate update for the ...

  • ACCESSWIRElast month

    Chimerix, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / November 8, 2017 / Chimerix, Inc. (NASDAQ: CMRX ) will be discussing their earnings results in their Q3 Earnings Call to be held on November 8, 2017 at 8:30 AM Eastern Time. ...

  • GlobeNewswirelast month

    Chimerix to Present at the Stifel 2017 Healthcare Conference

    DURHAM, N.C., Nov. 07, 2017-- Chimerix, a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced that M. Michelle Berrey, M.D., M.P.H., Chief Executive Officer ...

  • GlobeNewswire2 months ago

    Chimerix to Announce Third Quarter 2017 Financial Results on November 8, 2017

    DURHAM, N.C., Nov. 01, 2017-- Chimerix, Inc., a biopharmaceutical company discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients, today announced that ...

  • Capital Cube2 months ago

    ETFs with exposure to Chimerix, Inc. : October 11, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Chimerix, Inc. Here are 5 ETFs with the largest exposure to CMRX-US. Comparing the performance and risk of Chimerix, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of CMRX earnings conference call or presentation 7-Aug-17 12:30pm GMT

    Q2 2017 Chimerix Inc Earnings Call

  • GlobeNewswire3 months ago

    Chimerix to Present at Cantor Fitzgerald Global Healthcare Conference

    DURHAM, N.C., Sept. 20, 2017-- Chimerix, a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced that M. Michelle Berrey, M.D., M.P.H., President and Chief ...

  • Capital Cube4 months ago

    ETFs with exposure to Chimerix, Inc. : August 31, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Chimerix, Inc. Here are 5 ETFs with the largest exposure to CMRX-US. Comparing the performance and risk of Chimerix, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Chimerix, Inc. :CMRX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
    Capital Cube4 months ago

    Chimerix, Inc. :CMRX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017

    Categories: Yahoo FinanceGet free summary analysis Chimerix, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Chimerix, Inc. – Emergent BioSolutions Inc., Newlink Genetics Corporation, Merck & Co., Inc., Vical Incorporated, Novavax, Inc., Gilead Sciences, Inc. and Johnson & Johnson (EBS-US, NLNK-US, MRK-US, VICL-US, NVAX-US, ... Read more (Read more...)

  • Chimerix (CMRX) Q2 Loss Narrower than Expected, Revenues Down
    Zacks4 months ago

    Chimerix (CMRX) Q2 Loss Narrower than Expected, Revenues Down

    Chimerix (CMRX) revenues in Q2 were hurt by reduced reimbursable expenses related to the company's BARDA developmental contract.

  • Associated Press4 months ago

    Chimerix reports 2Q loss

    On a per-share basis, the Durham, North Carolina-based company said it had a loss of 36 cents. The results surpassed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...

  • ACCESSWIRE4 months ago

    Investor Network: Chimerix, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 7, 2017 / Chimerix, Inc. (NASDAQ: CMRX ) will be discussing their earnings results in their Q2 Earnings Call to be held August 7, 2017 at 8:30 AM Eastern Time. To listen ...

  • Capital Cube6 months ago

    ETFs with exposure to Chimerix, Inc. : June 27, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Chimerix, Inc. Here are 5 ETFs with the largest exposure to CMRX-US. Comparing the performance and risk of Chimerix, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Capital Cube6 months ago

    ETFs with exposure to Chimerix, Inc. : June 5, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Chimerix, Inc. Here are 5 ETFs with the largest exposure to CMRX-US. Comparing the performance and risk of Chimerix, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Chimerix, Inc. :CMRX-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017
    Capital Cube7 months ago

    Chimerix, Inc. :CMRX-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017

    Categories: Yahoo FinanceGet free summary analysis Chimerix, Inc. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of Chimerix, Inc. – Emergent BioSolutions Inc., Newlink Genetics Corporation, Merck & Co., Inc., Vical Incorporated, SIGA Technologies Inc, Novavax, Inc., Gilead Sciences, Inc. and Johnson & Johnson (EBS-US, NLNK-US, ... Read more (Read more...)

  • Associated Press7 months ago

    Chimerix reports 1Q loss

    The Durham, North Carolina-based company said it had a loss of 38 cents per share. The results fell short of Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment ...

  • Accesswire7 months ago

    Investor Network: Chimerix, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / May 9, 2017 / Chimerix, Inc. (NASDAQ: CMRX ) will be discussing their earnings results in their Q1 Earnings Call to be held May 9, 2017 at 8:30 AM Eastern Time. To listen to ...